Clinical Trial Update: Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update covers neoadjuvant regimens FEC, EC-T, or TC for locally advanced breast cancer and reports on pathological complete response rates.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Zhiyong Yu | Conditions: Breast Cancer, Pathological Complete Response | Phase 2, Phase 3 | Status: UNKNOWN